Loading
A phase 2 trial of Decitabine in acute myeloid leukaemia, run by Bio-Path Holdings, Inc., now recruiting.
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML is a phase 2 interventional study registered as NCT02781883 by Bio-Path Holdings, Inc., with 108 participants planned, started 2016-05 and due to reach its primary completion in 2027-12. Interventions recorded: BP1001 in combination with Ventoclax plus decitabine and BP1001 plus decitabine.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Acute myeloid leukaemia in older or unfit patients, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia in older or unfit patients, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia in older or unfit patients, Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia in older or unfit patients, Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia in older or unfit patients, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia in older or unfit patients, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia and the tag pipeline.
Shares Decitabine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET) and the tag pipeline.
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/